Pieter Wolters

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Priority Telecom BV provides telecommunication services. It offers solutions to businesses and governments in the Netherlands, Austria and Norway. The company also provides services to the healthcare, educational, financial, security and retail markets. Priority Telecom uses market and customer segmentation based on the size of activities, market sector, one or more locations, centralized of spread out applications and the business ambitions. The company was founded in 1998 and is headquartered in Schiphol-Rijk, the Netherlands.

IsoTis SA develops biomedical products. Its product include proprietary natural and synthetic bone graft substitutes and other related medical devices. These devices are used to enhance the repair and regeneration of bone in spinal and trauma surgery, joint replacements and dental applications. IsoTis' products are primarily used spinal fusion, trauma, joint revision, bone void filling and iliac crest backfills procedures. The company is headquartered in Lausanne, Switzerland.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Medica Venture Partners (Medica Venture Partners) is a venture capital firm founded in 1995 by Yuval Binur, Ehud Geller and Jonathan Fleming. The firm is headquartered in Israel.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Ester Neurosciences Ltd. engages in the research and development of screening assays. The company was founded on June 17, 1997 and is headquartered in Tel Aviv, Israel.

Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom.

Isobionics BV operates as a holding company, which produces flavor and fragrance ingredients. The firm manufactures and supplies natural chemical substances such as Valencene, Nootkatone, and Beta-Elemene. The company was founded by Toine Janssen in 2008 and is headquartered in Geleen, the Netherlands.

BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland.

Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.

Athyrium Capital Management LP (Athyrium) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Jeffrey A. Ferrell in 2008 as Athyrium Capital Management LLC and converted from a Delaware limited liability company to a Delaware limited partnership in 2015. Athyrium provides advisory services on a discretionary basis to its clients, which may include specific tailored vehicles and pooled investment vehicles intended for sophisticated investors and institutional investors.

QBIC Venture Partners BVBA (QBIC Venture Partners) is a venture capital firm founded in 2012 by Marc Zabeau. The firm is headquartered in Belgium.

Brightlands Venture Partners is an independent regional venture capital firm headquartered in Brightlands, Netherlands. The firm was founded in 2004.

Greentown Labs operates as a community of climatetech and cleantech pioneers working to design a more sustainable world. The company was founded in 2011 and is headquartered in Somerville, MA.

Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom.

Part of Intas Pharmaceuticals Ltd., Essential Pharmaceuticals LLC is a company that manufactures and markets pharmaceutical products. The company is based in Durham, NC. The company was founded in 2006. Emma Jane Johnson has been the CEO of the company since 2023. Essential Pharmaceuticals was acquired by Accord Healthcare, Inc. on July 26, 2017.

Clean Energy Venture Management LLC (Clean Energy Venture) is a venture capital firm founded in 2017 by Daniel P. Goldman, David S. Miller and Temple Fennell. The firm is headquartered in Boston, Massachusetts.

Essential Pharmaceuticals Ltd. manufactures pharmaceutical products. The company was founded on November 24, 2010 and is headquartered in Egham, the United Kingdom.

Prime Coalition, Inc. is a public charity that was founded by Matthew McLean Nordan in 2014. The American company has steered over $300 million in partnership with 250+ catalytic investors. Prime Coalition's first impact-first pooled vehicle, Prime Impact Fund, is a 100% catalytic capital fund that made its 16th and final investment in 2021. The private company now has over 30 companies in its venture portfolio in total. Prime Coalition collaborates to build open source tools and convenes to organize investors to improve forward-looking emissions impact methodologies and reporting best practices for climate-driven investments. The company partners with philanthropists to invest catalytic capital in extraordinary companies and projects that combat climate change, have a high likelihood of achieving commercial success, and are otherwise unlikely to be sufficiently supported toward optimal greenhouse gas emissions reduction potential.

Fibriant BV is a Dutch biotechnology company that specializes in the recombinant manufacturing and characterization of specific variants of human Fibrinogen and active human Thrombin. The company is based in Leiden, the Netherlands. The company's science and technology are centered around Fibrinogen, a soluble blood protein that can be converted into an insoluble three-dimensional Fibrin network. Fibriant captures the unique features and functions of specific recombinant variants of Fibrinogen in new innovative products and in improvements of existing products based on plasma Fibrinogen. The company was founded in 2015 by Jaap Koopman, Jos Grimbergen, Miranda Weggeman, and Jaap Koopman has been the CEO since then.

VOID Technologies Ltd. is a British company that manufactures polyethylene film. The company is based in Beaconsfield, UK. The company was founded in 2014.

Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands.